logo
IVF technique using DNA from 3 people spared children from inherited diseases, scientists say

IVF technique using DNA from 3 people spared children from inherited diseases, scientists say

CTV News17-07-2025
Eight children in the U.K. have been spared from devastating genetic diseases thanks to a new three-person in vitro fertilization technique, scientists from Newcastle University reported on Wednesday.
The technique, which is banned in the United States, transfers pieces from inside the mother's fertilized egg - its nucleus, plus the nucleus of the father's sperm - into a healthy egg provided by an anonymous donor.
The procedure prevents the transfer of mutated genes from inside the mother's mitochondria - the cells' energy factories - that could cause incurable and potentially fatal disorders.
Mutations in mitochondrial DNA can affect multiple organs, particularly those that require high energy, such as the brain, liver, heart, muscles and kidneys.
One of the eight children is now 2 years old, two are between ages 1 and 2, and five are infants. All were healthy at birth, with blood tests showing no or low levels of mitochondrial gene mutations, the scientists reported in the New England Journal of Medicine. All have made normal developmental progress, they said.
The results 'are the culmination of decades of work,' not just on the scientific/technical challenges but also in ethical inquiry, public and patient engagement, law-making, drafting and execution of regulations, and establishing a system for monitoring and caring for the mothers and infants, reproductive medicine specialist Dr. Andy Greenfield of the University of Oxford, who was not involved in the research, said in a statement.
The researchers' 'treasure trove of data' is likely to be the starting point of new avenues of investigation, Greenfield said.
Often during IVF screening procedures, doctors can identify some low-risk eggs with very few mitochondrial gene mutations that are suitable for implantation.
But sometimes all of the eggs' mitochondrial DNA carries mutations. In those cases, using the new technique, the UK doctors first fertilize the mother's egg with the father's sperm. Then they remove the fertilized egg's 'pronuclei' – that is, the nuclei of the egg and the sperm, which carry the DNA instructions from both parents for the baby's development, survival and reproduction.
Next, they transfer the egg and sperm nuclei into a donated fertilized egg that has had its pronuclei removed.
The donor egg will now begin to divide and develop with its healthy mitochondria and the nuclear DNA from the mother's egg and the father's sperm.
This process, detailed in a second paper in the journal, 'essentially replaces the faulty mitochondrial DNA (mtDNA) with healthy mtDNA from the donor,' senior researcher Mary Herbert, professor of reproductive biology at Newcastle, said at a press briefing.
Blood levels of mtDNA mutations were 95% to 100% lower in six newborns, and 77% to 88% lower in two others, compared to levels of the same variants in their mothers, the researchers reported in a second paper.
'These data indicate that pronuclear transfer was effective in reducing transmission of mtDNA disease,' they said.
The procedure was tested in 22 women whose babies were likely to inherit such genes. In addition to the eight women who delivered the children described in this report, another one of the 22 is currently pregnant.
Seven of the eight pregnancies were uneventful; in one case, a pregnant woman had blood tests showing high lipid levels.
There have been no miscarriages.
The authors of the current reports have also tried transplanting the nucleus of a mother's unfertilized egg into a donor egg and then fertilizing the donor egg afterward, but they believe their new approach may more reliably prevent transmission of the genetic disorders.
In 2015, the UK became the first country in the world to legalize research into mitochondrial donation treatment in humans.
That same year in the United States, pronuclear transfer was effectively banned for human use by a congressional appropriations bill that prohibited the Food and Drug Administration from using funds to consider the use of 'heritable genetic modification.'
Reporting by Nancy Lapid; Editing by Michele Gershberg and Lisa Shumaker, Reuters
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

Globe and Mail

timea day ago

  • Globe and Mail

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.

Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma
Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma

National Post

time3 days ago

  • National Post

Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma

Article content OTTAWA, Ontario & YORK, England — Genvira Biosciences Inc. ('Genvira'), a Canadian innovator in next-generation viral vectors, Labskin Limited ('Labskin'), a leader in 3D in vitro human skin models, and the National Research Council of Canada (NRC) are pleased to announce the launch of a collaborative project to develop novel immunotherapies for malignant melanoma. The collaboration is receiving advisory services and up to £1.2 million ($2.0 million) in funding through the Canada–UK Biomanufacturing of Biologics and Advanced Therapies program. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP). Article content Malignant melanoma continues to be a serious global health concern, with an estimated 330,000 new cases and 60,000 deaths each year. This international partnership aims to address the unmet need by developing cutting-edge cancer vaccines and optimizing targeted antigen delivery systems. Article content As part of the collaboration, Labskin will utilize its expertise in advanced disease modeling to develop a novel 3D human skin model of melanoma, enabling in vitro testing of vaccine candidates. Genvira will contribute its proprietary viral vector and gene delivery platforms, while the NRC will support the integration of mRNA technologies to engineer innovative, targeted immunotherapies tailored to melanoma. Article content Dr. Nicola Kingswell Article content , Scientific Director at Labskin Limited, stated: Article content 'We're extremely grateful to Innovate UK for supporting this exciting project. It represents a step-change in the treatment of malignant melanoma, which will benefit many patients worldwide. This partnership will not only produce and validate new immunotherapies, but also establish a framework for developing future cancer therapeutics.' Article content Dr. Jiahu Wang Article content , President of Genvira Biosciences, added: Article content 'We'd like to thank NRC IRAP for their support, and the NRC for their collaborative role. This partnership enables us to rapidly translate our viral vector technologies into clinical applications for melanoma and lays the groundwork for broader advances in cancer immunotherapy.' Article content The project brings together unique and complementary strengths in 3D tissue engineering, gene and viral therapy, mRNA technology, and advanced biomanufacturing. In addition to therapeutic development, the consortium will focus on scalable production processes, quality control assays, and robust technologies to enable rapid response to future healthcare challenges. Article content This initiative highlights the importance of international collaboration in driving innovation and accelerating the development of advanced biologics and therapies. Article content About Labskin Limited Article content Labskin Limited is a UK-based biotechnology company specializing in full-thickness human skin models for pharmaceutical, cosmetic, and clinical research. Its advanced 3D platforms offer realistic testing environments for evaluating treatments in vitro. Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store